Clarity expands pipeline with Cu-64/67 SAR-trastuzumab
Filed with ASX · · 4 pages · English
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Clarity to present COBRA and CLARIFY abstracts
- Clarity receives U.S. FDA Fast Track Designation
- Novel FAP-targeted radiopharmaceutical
- S&P DJI Announces December 2024 Quarterly Rebalance
- Last patient assessment completed for SARTATE trial
Later from Clarity Pharmaceuticals
- Clarity receives US FDA FTD for the treatment of mCRPC
- Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA
- Appendix 4D
- Clarity signs Cu-64 Supply Agreement with UQ
- SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences.
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals